AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PARADIGM BIOPHARMACEUTICALS

0.315

0.000

Volume:281.97K

Turnover:89.33K

Market Cap:136.54M

PE:-5.28

High:0.320

Open:0.320

Low:0.315

Close:0.315

52wk High:0.660

52wk Low:0.255

Shares:433.46M

Float Shares:353.07M

Volume Ratio:1.49

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.060

EPS(LYR):-0.060

ROE:-81.66%

ROA:-55.11%

PB:6.45

PE(LYR):-5.28

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies+1.30%

Capital Flow

Inflow:

Outflow:

News

BRIEF-Paradigm Biopharmaceuticals Signs Binding Veterinary Licensing & Supply Agreement

Paradigm Biopharmaceuticals Secures Binding Term Sheet With Veterinary Pharmaceutical Company; Shares Up 3%

MT Newswires Live

Paradigm Biopharmaceuticals Ltd - Signs Binding Veterinary Licensing & Supply Agreement for Oral PPS + Cox-2 Inhibitor Combination

THOMSON REUTERS

Paradigm Biopharmaceuticals -Co Eligible to Receive up to a$1 Mln From Avet in Development Milestones

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PAR.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PAR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","market":"AU","secType":"STK","nameCN":"PARADIGM BIOPHARMACEUTICALS","latestPrice":0.315,"timestamp":1770681737053,"preClose":0.315,"halted":0,"volume":281974,"delay":0,"changeRate":0,"nameEN":"PARADIGM BIOPHARMACEUTICALS","floatShares":353065639,"shares":433460088,"eps":-0.059699,"marketStatus":"Trading","change":0,"latestTime":"02-10 11:03:53 AEDT","open":0.32,"high":0.32,"low":0.315,"amount":89330,"amplitude":0.015873,"askPrice":0.32,"askSize":230587,"bidPrice":0.315,"bidSize":75087,"shortable":3,"etf":0,"ttmEps":-0.059699,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770699600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.315,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":1.486263,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","floatShares":353065639,"roa":"-55.11%","roe":"-81.66%","lyrEps":-0.059684,"volumeRatio":1.486263,"shares":433460088,"dividePrice":0,"high":0.32,"amplitude":0.015873,"preClose":0.315,"low":0.315,"week52Low":0.255,"pbRate":"6.45","psRate":"8176.04","week52High":0.66,"institutionHeld":0,"latestPrice":0.315,"committee":-0.508712,"eps":-0.059699,"divideRate":0,"volume":281974,"delay":0,"ttmEps":-0.059699,"open":0.32,"prevYearClose":0.34,"prevWeekClose":0.29,"prevMonthClose":0.305,"prevQuarterClose":0.34,"fiveDayClose":0.315,"twentyDayClose":0.345,"sixtyDayClose":0.365,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PAR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-02-06","symbol":"PAR.AU","defaultRemindTime":1738796400000,"type":"split","dateTimestamp":1738760400000,"forFactor":4,"toFactor":5,"ratio":0.8},{"market":"AU","date":"2022-08-17","symbol":"PAR.AU","defaultRemindTime":1660694400000,"type":"split","dateTimestamp":1660658400000,"forFactor":992772,"toFactor":1000000,"ratio":0.992772}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PAR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PAR.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610350119","title":"BRIEF-Paradigm Biopharmaceuticals Signs Binding Veterinary Licensing & Supply Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2610350119","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610350119?lang=en_us&edition=fundamental","pubTime":"2026-02-09 09:42","pubTimestamp":1770601357,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Signs Binding Veterinary Licensing & Supply AgreementFeb 9  - Paradigm Biopharmaceuticals Ltd PAR.AX:SIGNS BINDING VETERINARY LICENSING & SUPPLY AGREEMENT FOR ORAL PPS + COX-2 INHIBITOR COMBINATIONCO ELIGIBLE TO RECEIVE UP TO A$1 MILLION FROM AVET IN DEVELOPMENT MILESTONESFurther company coverage: PAR.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nFWN3Z21W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2610506213","title":"Paradigm Biopharmaceuticals Secures Binding Term Sheet With Veterinary Pharmaceutical Company; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610506213","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610506213?lang=en_us&edition=fundamental","pubTime":"2026-02-09 08:42","pubTimestamp":1770597732,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  secured a binding term sheet with AVet Health for the co-development and licensing of an oral combination therapy for the treatment of osteoarthritis in companion animals, according to a Monday filing with the Australian bourse.AVet Health will hold exclusive rights in Australia and New Zealand under the deal, with a first right of refusal for all other markets excluding the US, with the company eligible to receive up to AU$1 million in development milestones, the filing said.Once the licensing agreement is finalized, the company will receive tiered royalties of up to 20% on net sales and run for 15 years post-registration with the Australian Pesticides and Veterinary Medicines Authority, per the filing.Paradigm Biopharmaceuticals shares rose 3% in morning trade on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","PAR.AU","BK7067"],"gpt_icon":0},{"id":"2610508204","title":"Paradigm Biopharmaceuticals Ltd - Signs Binding Veterinary Licensing & Supply Agreement for Oral PPS + Cox-2 Inhibitor Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2610508204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610508204?lang=en_us&edition=fundamental","pubTime":"2026-02-09 06:08","pubTimestamp":1770588502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nFWN3Z21W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2610150820","title":"Paradigm Biopharmaceuticals -Co Eligible to Receive up to a$1 Mln From Avet in Development Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2610150820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610150820?lang=en_us&edition=fundamental","pubTime":"2026-02-09 06:08","pubTimestamp":1770588502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nFWN3Z21W1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAR.AU","BK7508","BK7067"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PAR.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":0.012956}]}}